H

Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566

Watchlist Manager
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Watchlist
Price: 29.92 CNY -0.56% Market Closed
Market Cap: 27.4B CNY
Have any thoughts about
Hubei Jumpcan Pharmaceutical Co Ltd?
Write Note

Net Margin
Hubei Jumpcan Pharmaceutical Co Ltd

31.2%
Current
26%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
31.2%
=
Net Income
2.8B
/
Revenue
8.9B

Net Margin Across Competitors

Country CN
Market Cap 27.6B CNY
Net Margin
31%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 755.8B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 351.1B USD
Net Margin
17%
Country US
Market Cap 251.8B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.5B USD
Net Margin
7%
No Stocks Found

Hubei Jumpcan Pharmaceutical Co Ltd
Glance View

Market Cap
27.6B CNY
Industry
Pharmaceuticals

In the bustling landscape of China's pharmaceutical industry, Hubei Jumpcan Pharmaceutical Co Ltd stands as a key player, weaving together tradition and modernity. Founded in 1951, this company has curated a journey of evolution—from its roots in the rich tapestry of traditional Chinese medicine to its current standing as a significant contributor to the healthcare sector. Core to Jumpcan's operation is its production and distribution of a diverse array of pharmaceutical products that span across various therapeutic areas, including digestive health, dermatology, and respiratory care. With an adept focus on over-the-counter medications and prescription drugs, Jumpcan effectively meets the health needs of a broad demographic, leveraging both the enduring appeal of traditional remedies and the growing demand for contemporary medical solutions. The business prowess of Jumpcan is deeply entwined with its strategy of innovation and adherence to quality standards, ensuring its pharmaceutical offerings are not only effective but also safe for consumption. Anchored in robust R&D initiatives, the company continues to enhance its product line, incorporating advanced technology and scientific research to produce medicines that align with global quality benchmarks. Furthermore, Jumpcan thrives on an extensive distribution network that spans across China, ensuring widespread accessibility of its products. By maintaining a keen understanding of the market dynamics and consumer preferences, Jumpcan artfully aligns its operations to capitalize on both domestic and international opportunities, thus solidifying its financial standing and perpetuating its growth within the dynamic corridors of the pharmaceutical industry.

Intrinsic Value
47.78 CNY
Undervaluation 37%
Intrinsic Value
Price
H

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
31.2%
=
Net Income
2.8B
/
Revenue
8.9B
What is the Net Margin of Hubei Jumpcan Pharmaceutical Co Ltd?

Based on Hubei Jumpcan Pharmaceutical Co Ltd's most recent financial statements, the company has Net Margin of 31.2%.